Abstract
Single chain variable fragment (scFv) constructs have been an important source of high affinity reagents to target cancer cells. Including an immunoglobulin Fc-binding domain can empower scFvs and other tumor antigen-binding proteins with immune effector cell functions and hence significantly increase their therapeutic potential.